About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Clinicaltrials.gov identifier NCT03932526

Recruitment Status Not yet recruiting

First Posted April 30, 2019

Last update posted April 30, 2019

Study Description

Brief summary:

To compare the therapeutic effect of vinorelbine used alone or combined with apatinib mesylate for recurrent or metastatic TNBC patients who have at least received one chemotherapy regimen, including anthracyclines and taxanes, providing clinical evidence for multi-line treatment options for advanced TNBC.

  • Condition or Disease:Triple-negative Breast Cancer
  • Intervention/Treatment: Drug: Vinorelbine + placebo
    Drug: Vinorelbine + Apatinib
  • Phase: Phase 2
Detailed Description

The emergence of new molecular targeted drugs provides new prospects for the treatment of advanced breast cancer; and its future therapeutic trend includes chemotherapy combined with molecular targeted therapy. Apatinib mesylate (Aitan), a novel small molecule anti-angiogenic agent, highly selectively inhibits the activity of vascular endothelial growth factor receptor-2 tyrosine kinase. Aitan also blocks the signaling of vascular endothelial growth factor binding to its receptor, thereby strongly inhibiting tumor angiogenesis and exerting anti-tumor effect.However, a randomized controlled clinical trial of apatinib combined with vinorelbine for TNBC has not been reported. The objective of this study is to compare the therapeutic effect of vinorelbine alone or combined with apatinib mesylate for recurrent or metastatic triple-negative breast cancer (TNBC) patients who have received at least two regimens containing anthracyclines and taxanes.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 184 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment
  • Official Title: Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Recurrent or Metastatic Triple-negative Breast Cancer: a Double-blinded Randomized Controlled Clinical Trial
  • Estimated Study Start Date: June 2019
  • Estimated Primary Completion Date: December 2022
  • Estimated Study Completion Date: June 2023
Arms and interventions
Arm Intervention/treatment
Active Comparator: Vinorelbine + placebo group
92 enrolled patients will be assigned to receive oral vinorelbine plus placebo until disease progression or other criteria for administration termination.
Drug: Vinorelbine + placebo
Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.
Experimental: Vinorelbine + Apatinib group
92 enrolled patients will be assigned to receive oral patatinib mesylate in combination with vinorelbine until disease progression or other criteria for administration termination.
Drug: Vinorelbine + Apatinib
Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
Outcome Measures
  • Primary Outcome Measures: 1. Progress-Free Survival(PFS) [ Time Frame: Day 1 of treatment until disease progression or death from any cause, assessed up to 24 months ]
    PFS refers to the length of time from random enrollment to any recorded tumor progression or death from any cause.
  • Secondary Outcome Measures: 1. Overall survival (OS) [ Time Frame: Up to 24 months ]
    OS indicates the length of time from enrollment to death from any cause.When no information on death is collected in the clinical database, the last date when the patient is still known to have survived is used as the cut-off point.
  • 2. Disease control rate (DCR) [ Time Frame: Up to 24 months ]
    DCR indicates the percentage of patients with CR, partial remission, and disease stabilization; and maintenance over 4 weeks, accounts for all the subjects with evaluable efficacy.
  • 3. Overall remission rate (ORR) [ Time Frame: Up to 24 months ]
    ORR is the proportion of patients who achieve a complete or partial response ((CR+PR)/total number of cases x 100%), as assessed by the RECIST v1.1.
  • 4. Adverse events at levels 3 and 4 [ Time Frame: every 6 weeks (two cycles) and 4 weeks after treatment discontinuation ]
    Patients with adverse events at levels 3 and 4 will be assessed according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 4.0.
Eligibility Criteria
  • Ages Eligible for Study: 18 to 70 Years (Adult, Older Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Female patients with recurrent or metastatic TNBC, as confirmed by histological or
cytological examination

- Age 18-70 years old

- According to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,
there is at least one measurable lesion.

- The Eastern Cooperative Oncology Group (ECOG) scores 0-2

- Expected survival ≥ 12 weeks

- Negative for ER/PR

- All patients will be tested for bone marrow capacity, liver and renal functions within
7 days prior to enrollment

- Previous use of anthracyclines and/or taxanes

- The medication history of vinorelbine

- Female patients of childbearing age must take adequate contraception; otherwise the
patients must be proven to be infertile

- No history of serious heart, lung, liver, and kidney diseases

- Provision of written informed consent

Exclusion Criteria:

- Patients who receive chemotherapy, radiation therapy, targeted drugs, or hormone
therapy within 3 weeks of administration

- Patients using corticosteroids for untreated brain or subdural metastatic lesions,
need to have stopped it, at least for 4 weeks or until there are no signs of brain
metastasis and/or symptoms must have stabilized for at least 4 weeks, if local
treatment has been completed. Enhanced computed tomography (CT) or magnetic resonance
imaging (MRI) images during screening are compared with those performed at least 4
weeks earlier to determine radiological stability.

- Patients with severe vascular diseases, including unstable angina, myocardial
infarction, or severe arrhythmia in the past 6 months

- History of HIV infection or active chronic hepatitis B or C

- Patients with other serious infectious diseases

- Patients positive for ER/PR/HER-2 positive

- Patients with allogeneic organ transplants requiring immunosuppressive therapy

- History of other malignant tumors within 5 years, except for cured cervical carcinoma
in situ or basal cell carcinoma of the skin

- Other destabilizing factors that may interfere with patients or have an impact on the
trial results

- Allergic to target drugs or allergic to related drugs applied in the trial

- Pregnant or lactating women

Contacts and Locations
Contacts

Contact: Tao Sun, M.D. 86-024-31986682 jianong@126.com

Locations
Sponsors and Collaborators

Liaoning Tumor Hospital & Institute

Investigators

Principal Investigator: Tao Sun Liaoning Tumor Hospital & Institute

More Information
  • Responsible Party: Liaoning Tumor Hospital & Institute
  • ClinicalTrials.gov Identifier: NCT03932526 History of Changes
  • Other Study ID Numbers: STao-003
  • First Posted: April 30, 2019 Key Record Dates
  • Last Update Posted: April 30, 2019
  • Last Verified: April 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Breast Neoplasms Triple Negative Breast Neoplasms